In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Input: Consider Input: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Budget Surplus Dividend Act of
1997''.

SEC. 2. 50 PERCENT OF FEDERAL BUDGET SURPLUS TO REIMBURSE EMPLOYERS AND
EMPLOYEES FOR A PORTION OF THEIR SOCIAL SECURITY TAXES.

(a) In General.--Subpart C of part IV of subchapter A of chapter 1
of the Internal Revenue Code of 1986 (relating to refundable credits)
is amended by redesignating section 35 as section 36 and by inserting
after section 34 the following new section:

''SEC. 35. CREDIT FOR PORTION OF SOCIAL SECURITY TAXES.

''(a) Allowance of Credit.--In the case of a taxable year to which
this section applies, there shall be allowed as a credit against the
tax imposed by this subtitle for the taxable year an amount equal to
the applicable percentage of the taxpayer's social security taxes for
the taxable year.
''(b) Taxable Years to Which Section Applies.--This section shall
apply to any taxable year beginning in the first calendar year
beginning after a fiscal year if there is a Federal budget surplus for
such fiscal year of more than $1,000,000,000.
''(c) Applicable Percentage.--For purposes of this section--
''(1) In general.--The term 'applicable percentage' means--
''(A) the base percentage with respect to so much
of the taxpayer's social security taxes as does not
exceed $3,000, and
''(B) the phasedown percentage with respect to so
much of the taxpayer's social security taxes as exceeds
$3,000.
''(2) Base percentage.--The term 'base percentage' means,
for taxable years beginning in a calendar year, the percentage
which the Secretary estimates will result in a reduction of
revenues to the Treasury by reason of this section for such
taxable year equal to 50 percent of the Federal budget surplus
for the most recent fiscal year ending before such calendar
year. Proper adjustments shall be made in the percentage
determined under the preceding sentence with respect to any
subsequent fiscal year to the extent that prior estimates were
in excess of or less than the proper percentage.
''(3) Phasedown percentage.--The term 'phasedown
percentage' means the base percentage reduced (but not below
zero) by the number of percentage points which bears the same
ratio to the base percentage as--
''(A) the excess of the taxpayer's social security
taxes over $3,000 bears to
''(B) the excess of the maximum social security
taxes over $3,000.
''(4) Maximum social security taxes.--The term 'maximum
social security taxes' means the amount which would be the
social security taxes of the taxpayer if the amount on which
such taxes are determined were equal to the maximum amount of
remuneration which may be taken into account under section
3101(a).
''(5) Special rules.--
''(A) Dollar limitations on per employee basis.--
The dollar limitations in paragraphs (1) and (3) shall
be applied on a per employee basis.
''(B) Self-employed individuals.--Paragraphs (1)
and (3) shall be applied by substituting '$6,000' for
'$3,000' each place it appears in the case of the taxes
referred to in subparagraph (C) or (D) of subsection
(d)(1).
''(d) Social Security Taxes.--For purposes of this section--
''(1) In general.--The term 'social security taxes' means,
with respect to any taxpayer for any taxable year--
''(A) the taxes imposed by sections 3101 and
3201(a) (relating to taxes on employees) on amounts
received by the taxpayer during the calendar year in
which the taxable year begins,
''(B) the taxes imposed by sections 3111 and
3221(a) (relating to taxes on employers) on amounts
paid by the taxpayer during the calendar year in which
the taxable year begins,
''(C) the taxes imposed by section 1401 on the
self-employment income of the taxpayer for the taxable
year, and
''(D) the taxes imposed by section 3211(a)(1) on
amounts received by the taxpayer during the calendar
year in which the taxable year begins.
''(2) Coordination with special refund of social security
taxes.--The term 'social security taxes' shall not include any
taxes to the extent the taxpayer is entitled to a special
refund of such taxes under section 6413(c).
''(3) Special rule.--Any amounts paid pursuant to an
agreement under section 3121(l) (relating to agreements entered
into by American employers with respect to foreign affiliates)
which are equivalent to the taxes referred to in paragraph
(1)(A) shall be treated as taxes referred to in such
paragraph.''
(b) Clerical Amendment.--The table of sections for subpart C of
part IV of subchapter A of chapter 1 of such Code is amended by
striking the item relating to section 35 and inserting the following:

''Sec. 35. Credit for portion of social
security taxes.
''Sec. 36. Overpayments of tax.''
(c) Effective Date.--The amendments made by this section shall
apply to taxable years beginning after December 31, 1997.

SEC. 3. APPROPRIATION TO USE 25 PERCENT OF FEDERAL BUDGET SURPLUS TO
REDUCE OUTSTANDING PUBLIC DEBT.

There is hereby appropriated for the first fiscal year following
each fiscal year for which there is a Federal budget surplus an amount
equal to 25 percent of such surplus for purpose of paying at maturity,
or to redeem or buy before maturity, obligations of the Government
included in the public debt. An obligation of the Government that is
paid, redeemed, or bought with funds appropriated by the preceding
sentence shall be canceled and retired and may not be reissued.

SEC. 4. USE 25 PERCENT OF FEDERAL BUDGET SURPLUS TO INCREASE NONDEFENSE
DISCRETIONARY SPENDING LIMITS.

For the first fiscal year following each fiscal year for which
there is a Federal budget surplus, the Director of the Office of
Management and Budget shall increase (on a pro rata basis between the
applicable nondefense categories for that fiscal year) the
discretionary spending limit for new budget authority under section
251(c) of the Balanced Budget and Emergency Deficit Control Act of 1985
by an amount equal to 25 percent of such surplus and shall adjust the
outlays flowing from that budget authority accordingly.

Output: Budget Surplus Dividend Act of 1997 - Amends the Internal Revenue Code to allocate credits to taxpayers for social security taxes, during any year in which there is a Federal budget surplus of more than $1 billion, so as to utilize 50 percent of such surplus. Requires that, during any such year, the remainder of such surplus shall be split and used to: (1) reduce the outstanding public debt; and (2) increase nondefense discretionary spending limits.

Input: Consider Input: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Captive Primate Safety Act''.

SEC. 2. ADDITION OF NONHUMAN PRIMATES TO DEFINITION OF PROHIBITED
WILDLIFE SPECIES.

Section 2(g) of the Lacey Act Amendments of 1981 (16 U.S.C.
3371(g)) is amended by inserting before the period at the end ''or any
nonhuman primate''.

SEC. 3. CAPTIVE WILDLIFE AMENDMENTS.

(a) Prohibited Acts.--Section 3 of the Lacey Act Amendments of 1981
(16 U.S.C. 3372) is amended--
(1) in subsection (a)--
(A) in paragraph (2)--
(i) in subparagraph (A), by inserting
''or'' after the semicolon;
(ii) in subparagraph (B)(iii), by striking
''; or'' and inserting a semicolon; and
(iii) by striking subparagraph (C); and
(B) in paragraph (4), by inserting ''or subsection
(e)'' before the period; and
(2) in subsection (e)--
(A) by redesignating paragraphs (2), (3), (4), and
(5) as paragraphs (3), (4), (5), and (6) respectively;
(B) by striking ''(e)'' and all that follows
through ''Subsection (a)(2)(C) does not apply'' in
paragraph (1) and inserting the following:
''(e) Captive Wildlife Offense.--
''(1) In general.--It is unlawful for any person to import,
export, transport, sell, receive, acquire, or purchase in
interstate or foreign commerce any live animal of any
prohibited wildlife species.
''(2) Limitation on application.--This subsection--
''(A) does not apply to a person transporting a
nonhuman primate to or from a veterinarian who is
licensed to practice veterinary medicine within the
United States, solely for the purpose of providing
veterinary care to the nonhuman primate, if--
''(i) the person transporting the nonhuman
primate carries written documentation issued by
the veterinarian, including the appointment
date and location;
''(ii) the nonhuman primate is transported
in a secure enclosure appropriate for that
species of primate;
''(iii) the nonhuman primate has no contact
with any other animals or members of the
public, other than the veterinarian and other
authorized medical personnel providing
veterinary care; and
''(iv) such transportation and provision of
veterinary care is in accordance with all
otherwise applicable State and local laws,
regulations, permits, and health certificates;
''(B) does not apply to a person transporting a
nonhuman primate to a legally designated caregiver for
the nonhuman primate as a result of the death of the
preceding owner of the nonhuman primate, if--
''(i) the person transporting the nonhuman
primate is carrying legal documentation to
support the need for transporting the nonhuman
primate to the legally designated caregiver;
''(ii) the nonhuman primate is transported
in a secure enclosure appropriate for the
species;
''(iii) the nonhuman primate has no contact
with any other animals or members of the public
while being transported to the legally
designated caregiver; and
''(iv) all applicable State and local
restrictions on such transport, and all
applicable State and local requirements for
permits or health certificates, are complied
with;
''(C) does not apply to a person transporting a
nonhuman primate solely for the purpose of assisting an
individual who is permanently disabled with a severe
mobility impairment, if--
''(i) the nonhuman primate is a single
animal of the genus Cebus;
''(ii) the nonhuman primate was obtained
from, and trained at, a licensed nonprofit
organization described in section 501(c)(3) of
the Internal Revenue Code of 1986 the nonprofit
tax status of which was obtained--
''(I) before July 18, 2008; and
''(II) on the basis that the
mission of the organization is to
improve the quality of life of severely
mobility-impaired individuals;
''(iii) the person transporting the
nonhuman primate is a specially trained
employee or agent of a nonprofit organization
described in clause (ii) that is transporting
the nonhuman primate to or from a designated
individual who is permanently disabled with a
severe mobility impairment, or to or from a
licensed foster care home providing specialty
training of the nonhuman primate solely for
purposes of assisting an individual who is
permanently disabled with severe mobility
impairment;
''(iv) the person transporting the nonhuman
primate carries documentation from the
applicable nonprofit organization that includes
the name of the designated individual referred
to in clause (iii);
''(v) the nonhuman primate is transported
in a secure enclosure that is appropriate for
that species;
''(vi) the nonhuman primate has no contact
with any animal or member of the public, other
than the designated individual referred to in
clause (iii); and
''(vii) the transportation of the nonhuman
primate is in compliance with--
''(I) all applicable State and
local restrictions regarding the
transport; and
''(II) all applicable State and
local requirements regarding permits or
health certificates; and
''(D) does not apply'';
(C) in paragraph (2) (as added by subparagraph
(B))--
(i) by striking ''a'' before ''prohibited''
and inserting ''any'';
(ii) by striking ''(3)'' and inserting
''(4)''; and
(iii) by striking ''(2)'' and inserting
''(3)'';
(D) in paragraph (3) (as redesignated by
subparagraph (A))--
(i) in subparagraph (C)--
(I) in clauses (ii) and (iii), by
striking ''animals listed in section
2(g)'' each place it appears and
inserting ''prohibited wildlife
species''; and
(II) in clause (iv), by striking
''animals'' and inserting ''prohibited
wildlife species''; and
(ii) in subparagraph (D), by striking
''animal'' each place it appears and inserting
''prohibited wildlife species'';
(E) in paragraph (4) (as redesignated by
subparagraph (A)), by striking ''(2)'' and inserting
''(3)''; and
(F) in paragraph (6) (as redesignated by
subparagraph (A))--
(i) by striking ''subsection (a)(2)(C)''
and inserting ''this subsection''; and
(ii) by striking ''2004 through 2008'' and
inserting ''2011 through 2015''.
(b) Civil Penalties.--Section 4(a) of the Lacey Act Amendments of
1981 (16 U.S.C. 3373(a)) is amended--
(1) in paragraph (1), by inserting ''(e),'' after
''subsections (b), (d),''; and
(2) in paragraph (1), by inserting '', (e),'' after
''subsection (d)''.
(c) Criminal Penalties.--Section 4(d) of the Lacey Act Amendments
of 1981 (16 U.S.C. 3373(d)) is amended--
(1) in paragraphs (1)(A) and (1)(B) and in the first
sentence of paragraph (2), by inserting ''(e),'' after
''subsections (b), (d),'' each place it appears; and
(2) in paragraph (3), by inserting '', (e),'' after
''subsection (d)''.
(d) Effective Date; Regulations.--
(1) Effective date.--Subsections (a) through (c), and the
amendments made by those subsections, shall take effect on the
earlier of--
(A) the date of promulgation of regulations under
paragraph (2); and
(B) the expiration of the period referred to in
paragraph (2).
(2) Regulations.--Not later than 180 days after the date of
enactment of this Act, the Secretary of the Interior shall
promulgate regulations implementing the amendments made by this
section.

SEC. 4. APPLICABILITY PROVISION AMENDMENT.

Section 3 of the Captive Wildlife Safety Act (117 Stat. 2871;
Public Law 108-191) is amended--
(1) in subsection (a), by striking ''(a) In General.--
Section 3'' and inserting ''Section 3''; and
(2) by striking subsection (b).

SEC. 5. REGULATIONS.

Section 7(a) of the Lacey Act Amendments of 1981 (16 U.S.C.
3376(a)) is amended by adding at the end the following:
''(3) The Secretary shall, in consultation with other
relevant Federal and State agencies, promulgate regulations to
implement section 3(e).''.

Output: Captive Primate Safety Act - Amends the Lacey Act Amendments of 1981 to add nonhuman primates to the definition of "prohibited wildlife species" for purposes of the prohibition against the sale or purchase of such species in interstate or foreign commerce.

Makes it unlawful for a person to import, export, transport, sell, receive, acquire, or purchase a live animal of any prohibited wildlife species in interstate or foreign commerce (i.e., for pet trade purposes). Sets forth exceptions to such prohibition, including, under certain conditions, for: (1) transporting a nonhuman primate to or from a veterinarian, (2) transporting a nonhuman primate to a legally designated caregiver as a result of the death of the preceding owner, and (3) transporting a single primate of the genus Cebus that was obtained from and trained by a charitable organization to assist a permanently disabled individual with a severe mobility impairment.

Sets forth civil and criminal penalties for violations of the requirements of this Act. Extends the authorization of appropriations to carry out such prohibition for FY2011-FY2015.

Input: Consider Input: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Generic Complex Drugs Safety and
Effectiveness for Patients Act of 2015''.

SEC. 2. GAO STUDY OF SCIENTIFIC ISSUES REGARDING THE CURRENT REGULATORY
PATHWAY FOR REVIEWING GENERIC VERSIONS OF CERTAIN COMPLEX
DRUG PRODUCTS.

(a) Study by GAO.--The Comptroller General of the United States
shall conduct a study to determine the following:
(1) With respect to nonbiologic complex drug products that
have not been fully characterized (as defined in subsection
(e)(1)), whether the listing of such drugs as reference
products in generic drug applications presents unique
challenges in meeting approval standards that are significantly
different than the challenges presented by generic drug
applications that list small-molecule reference products.
(2) With respect to biological products that are within the
scope of the exception under section 7002(e)(2) of Public Law
111-148 (relating to temporary authority for the approval of
biological products under section 505 of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 355)), whether the listing of
such biological products as reference products in generic drug
applications presents unique challenges in meeting approval
standards that are significantly different than the challenges
presented by generic drug applications that list small-molecule
reference products.
(3) If the answer to the question under paragraph (1) or
(2) is that significantly different challenges are presented
for patients when reference products are nonbiologic complex
drug products that have not been fully characterized or when
reference products are biological products that are within the
scope of the exception under section 7002(e)(2) of Public Law
111-148:
(A) What degree of characterization of the proposed
generic version and the reference product should be
required in order to determine the safety and
effectiveness of the generic version.
(B) What degree of similarity should be required to
deem that the active ingredient of the proposed generic
version is the same as the active ingredient of the
reference product.
(C) What types of evidence should be required to
demonstrate that the proposed generic version is
bioequivalent to the reference product.
(D) What requirements should be established with
respect to the comparability of the manufacturing
process for the proposed generic version and the
manufacturing process for the reference product.
(E) Whether and to what extent clinical evidence is
needed to demonstrate that there is no difference in
immunogenicity between the proposed generic version and
the reference product.
(F) Whether and to what extent other clinical
evidence is needed to demonstrate that the proposed
generic version is as safe and effective for patients
as the reference product.
(G) Taking into account the determinations made
regarding the issues listed in subparagraphs (A)
through (F):
(i) Whether section 505(j) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 355(j))
should be amended to establish provisions that
expressly address the approval of copy versions
of nonbiologic complex drug products that have
not been fully characterized, provisions that
expressly address the approval of copy versions
of biological products that are within the
scope of the exception under section 7002(e)(2)
of Public Law 111-148, or both.
(ii) Whether section 505(b)(2) of such Act
(21 U.S.C. 355(b)(2)) should be so amended.
(iii) Whether such Act should otherwise be
so amended.
(iv) Whether section 351 of the Public
Health Service Act (42 U.S.C. 262) should be so
amended.
(H) Taking into account the determinations made
regarding the issues listed in subparagraphs (A)
through (F), and taking into consideration all relevant
guidances, draft guidances, and other agency policy
documents--
(i) whether the Food and Drug
Administration should develop and provide to
the public a policy document that provides a
comprehensive statement of general principles
on the evidence that is necessary to obtain the
approval of such Administration for proposed
generic versions of reference products that are
nonbiologic complex drug products that have not
been fully characterized or that are biological
products; and
(ii) if so, the date by which such
Administration could reasonably be expected to
issue such comprehensive policy document.
(b) Consultation.--The Comptroller General shall conduct the study
under subsection (a) in consultation with--
(1) the Secretary of Health and Human Services, acting
through the Commissioner of Food and Drugs; and
(2) appropriate public and private entities, including
patient advocacy organizations, professional medical
associations, hospital pharmacies, scientists of academic and
business organizations, and representatives of the regulated
industry.
(c) Required Consideration.--In carrying out the study under
subsection (a), the Comptroller General shall consider the following:
(1) Published clinical reports of clinically meaningful
(including serious) adverse events of patients to--
(A) generic versions of the nonbiologic complex
drug products that have not been fully characterized;
(B) generic versions of biological products; and
(C) the reference products.
(2) The specific criteria that have been used by the
Secretary to approve generic versions of nonbiologic complex
drug products that have not been fully characterized or generic
versions of biological products.
(3) The specific criteria specified in guidances, draft
guidance, and other documents issued by the Secretary regarding
applications under section 351(k) of the Public Health Service
Act (42 U.S.C. 262(k)) for the licensing of biosimilar
biological products.
(d) Optional Consideration.--In carrying out the study under
subsection (a), the Comptroller General may under subsection (c)
consider the following information from foreign countries:
(1) Reports described in subsection (c)(1) from foreign
countries that are listed in clause (i) or (ii) of section
802(b)(1)(A) of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 382(b)(1)(A)) or are designated pursuant to section
802(b)(1)(B) of such Act (21 U.S.C. 382(b)(1)(B)).
(2) The guidelines or recommendations of the pharmaceutical
regulatory agencies of foreign countries described in paragraph
(1) regarding any class of products that such an agency
regulates as a biosimilar biological product, but that has been
or could be approved as a generic drug in the United States.
(3) Any instance where the Secretary or such foreign
regulatory agencies have, after approving a generic version (or
a foreign equivalent) of a nonbiologic complex drug product
that has not been fully characterized or a generic version (or
a foreign equivalent) of a biological product, sought a
clinical trial to confirm--
(A) the generic version (or foreign equivalent) is
therapeutically equivalent to the reference product (or
meets a similar standard, in the case of a foreign
regulatory agency); or
(B) the safety and effectiveness of the generic
version (or foreign equivalent).
(e) Completion Date.--Not later than the expiration of the 2-year
period beginning on the date of the enactment of this Act, the
Comptroller General shall complete the study under subsection (a) and
submit a report describing the findings and conclusions of the study to
the Secretary, the Committee on Energy and Commerce of the House of
Representatives, and the Committee on Health, Education, Labor, and
Pensions of the Senate.
(f) Definitions.--
(1) Complex drug product not fully characterized.--For
purposes of this section, the terms ''complex drug product that
has not been fully characterized'' and ''complex drug products
that have not been fully characterized'', with respect to a
nonbiologic drug, means a drug for which--
(A) the active ingredient has molecular diversity;
(B) scientific analytic methodologies are unable to
fully identify the molecular structures and
physiochemical properties of the active ingredient; and
(C) the nature of the active ingredient is not
understood sufficiently to identity--
(i) all the molecular components of the
drug that are involved in producing the
therapeutic effect; and
(ii) the mechanisms of action that produce
such effect.
(2) Other definitions.--For purposes of this section:
(A) The term ''bioequivalent'', with respect to a
generic drug, has the meaning given such term in
section 505(j)(8)(B) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 355(j)(8)(B)).
(B) The term ''generic drug'' or ''generic
version'', with respect to the United States, means a
drug that is approved under section 505(j) of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C.
355(j)).
(C) The term ''generic drug application'' means an
abbreviated application for the approval of a new drug
under section 505(j) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 355(j)).
(D) The term ''proposed'', with respect to a
generic version, means subject to a generic drug
application that is pending before the Food and Drug
Administration.
(E) The term ''reference product'', with respect to
a generic drug, has the meaning given the term ''listed
drug'' in section 505(j) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 355(j)).
(F) The term ''Secretary'' means the Secretary of
Health and Human Services.
Output: Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015 This bill requires the Government Accountability Office (GAO) to study whether generic versions of certain complex drugs or certain biological drugs face significantly different challenges in meeting the approval standards of the Food and Drug Administration (FDA) than generic versions of small-molecule drugs. (Complex drugs and biological drugs can be composed of large molecules that are more difficult to fully characterize than small molecules, so it can be more difficult to demonstrate that generic versions of these drugs are the same as the brand name versions.) If the GAO determines that these generic drugs face significantly different challenges, then the GAO must also determine: (1) the evidence that should be required to demonstrate that one of these generic drugs is sufficiently similar to the brand name drug in safety, composition, and activity; (2) whether the Federal Food, Drug, and Cosmetic Act should be amended to address the approval of these generic drugs; and (3) whether the FDA should develop a policy document on the evidence that is necessary to obtain approval of these generic drugs.